One To Watch

Emergence Therapeutics

A European antibody-drug conjugate developer acquired by Eli Lilly in August 2023 for up to $600 million, whose lead Nectin-4 ADC, ETx-22, was subsequently deprioritized inside Lilly's dual-track oncology program.

Company Overview

Emergence Therapeutics is a European antibody-drug conjugate developer acquired by Eli Lilly in August 2023 for up to $600 million, whose lead Nectin-4 ADC, ETx-22, was subsequently deprioritized inside Lilly's dual-track oncology program. The company built its platform around next-generation ADC design — engineering tumor-selective targeting and tumor-specific payload deconjugation to widen the therapeutic window over first-generation conjugates. Originally independent and privately held, Emergence now operates as a wholly owned Lilly subsidiary. Its scientific infrastructure spans Germany and France, absorbed into Lilly's oncology organization following the 2023 close.

Headquarters and Global Presence

Emergence Therapeutics is headquartered in Duisburg, Germany, with a subsidiary presence in Marseille, France. Both sites were integrated into Eli Lilly's operations following the August 2023 acquisition close.

Founding and History

Emergence Therapeutics was founded as a privately held European biotech focused on ADC engineering for solid tumors. Eli Lilly announced its intention to acquire the company on June 29, 2023, and completed the transaction on August 24, 2023, for an estimated upfront and milestone total of $470–600 million. The acquisition was driven by Lilly's strategic push to build a competitive ADC oncology franchise, with ETx-22's Nectin-4 targeting providing an entry point into a validated but contested space. Emergence now operates as a legal subsidiary of Lilly, retaining its corporate entity rather than being dissolved.

Therapy Areas and Focus

Emergence's scientific rationale centers on Nectin-4, a cell adhesion molecule overexpressed in a broad range of solid tumors — most prominently urothelial (bladder) cancer, triple-negative breast cancer, ovarian, head and neck, and lung cancer. The original ETx-22 program was explicitly designed to extend ADC utility beyond high-Nectin-4 expressors to tumors with medium and low expression, broadening the addressable patient population. Bladder cancer remains the most commercially significant indication, given that enfortumab vedotin, another Nectin-4 ADC, has already validated the target in this setting. The competitive question was always whether next-generation engineering could meaningfully improve on enfortumab's efficacy and tolerability profile.

Technology Platforms and Modalities

ETx-22 was designed as a next-generation Nectin-4 ADC with two distinguishing engineering features: selectivity for tumor-expressed Nectin-4 over normal tissue, and tumor-specific payload deconjugation intended to concentrate cytotoxic activity at the tumor site and reduce systemic toxicity. This approach directly targets the dose-limiting toxicities that constrain first-generation ADCs, where off-target payload release drives skin, ocular, and peripheral neuropathy side effects seen with enfortumab vedotin. The platform logic — improve the therapeutic index rather than simply swap the target — is a common architectural philosophy in the ADC field, though clinical translation of that engineering advantage has proven difficult to demonstrate consistently.

Key Pipeline and Programs

ETx-22, renamed LY4101174 within Lilly, was the lead asset from Emergence and entered a Phase I dose-escalation study (NCT06238479) evaluating safety and preliminary efficacy in advanced solid tumors. That study was terminated in April 2026 after enrolling 143 of 490 planned patients, with Lilly citing adjustments in development strategy — a formulation consistent with LY4052031, Lilly's other Nectin-4 ADC, generating more compelling early data. LY4052031, not derived from Emergence, is now the prioritized Nectin-4 program inside Lilly; its Nexus-01 study (NCT06465069) resumed recruitment in 2026 for patients with advanced or metastatic urothelial cancer and other Nectin-4-expressing solid tumors, including breast, cervix, lung, and ovarian cancers. The termination of LY4101174's Phase I effectively closes out the active clinical contribution of Emergence's original pipeline within Lilly's portfolio.

Recent Developments

In April 2026, Lilly terminated the Phase I study of LY4101174 (ETx-22) after enrolling only 143 of 490 planned patients, citing strategic reprioritization toward its other Nectin-4 ADC, LY4052031. The Nexus-01 study of LY4052031 (NCT06465069) subsequently resumed enrollment in 2026 for urothelial and other solid tumor indications. These decisions effectively resolved Lilly's internal competition between two Nectin-4 ADCs in favor of the asset not derived from the Emergence acquisition. No further independent pipeline activity from Emergence Therapeutics has been reported.

Key Personnel

Named executive leadership for Emergence Therapeutics as an independent entity has not been disclosed in available sources following its full integration into Eli Lilly's organizational structure in 2023. Pipeline decisions, including the April 2026 termination of LY4101174's Phase I study, are now made within Lilly's oncology development organization.

Strategic Partnerships

Emergence Therapeutics' sole disclosed strategic transaction is its acquisition by Eli Lilly, announced June 29, 2023, and closed August 24, 2023, for a reported total consideration of $470–600 million including milestones. As a wholly owned subsidiary, Emergence operates entirely within Lilly's development and commercial infrastructure, with no separately disclosed external partnerships or licensing agreements.

FAQ Section

Lilly paid up to $600 million for Emergence primarily to access ETx-22, a Nectin-4 ADC engineered with tumor-selective deconjugation intended to improve on the tolerability profile of enfortumab vedotin. The acquisition gave Lilly a second Nectin-4 asset to run in parallel with its internally developed LY4052031, enabling a head-to-head internal competition to identify the stronger candidate. That strategy ultimately resolved against the Emergence-derived asset in April 2026, when the LY4101174 Phase I was terminated.

Nectin-4 is a cell adhesion protein overexpressed in urothelial, breast, cervical, ovarian, lung, and head and neck cancers, making it a broadly applicable ADC target across high-volume solid tumor indications. The space was commercially validated when enfortumab vedotin, a Nectin-4 ADC developed by Astellas and Seagen, gained approval in bladder cancer and demonstrated strong survival data in combination with pembrolizumab. That validation drove multiple second-generation Nectin-4 ADC programs — including both Emergence's ETx-22 and Lilly's LY4052031 — but also raised the competitive bar considerably.

ETx-22 was engineered with tumor-specific deconjugation — the payload is designed to release selectively within the tumor microenvironment rather than systemically, targeting the off-target toxicities (skin reactions, peripheral neuropathy, ocular events) that limit enfortumab vedotin dosing. It was also designed to retain activity in tumors with medium and low Nectin-4 expression, expanding the addressable population beyond high-expressors. Whether that engineering translated into a clinically meaningful efficacy or safety advantage over enfortumab was never demonstrated, as the Phase I was terminated before generating comparative data.

LY4101174 entered a Phase I dose-escalation study (NCT06238479) designed to enroll 490 patients across advanced solid tumors. In April 2026, Lilly terminated the trial after only 143 patients had been enrolled, citing adjustments in development strategy. The contemporaneous decision to resume enrollment in the Nexus-01 study of LY4052031 makes the competitive dynamic clear: LY4052031 was generating stronger data, and running two broadly similar Nectin-4 ADCs was no longer warranted.

Emergence focused entirely on solid tumor oncology, with Nectin-4 expression as the molecular rationale linking its target indications. Primary focus was urothelial (bladder) cancer and triple-negative breast cancer — the highest Nectin-4 expressing tumor types — with secondary indications in ovarian, head and neck, and lung cancers where medium and low expression levels were considered actionable by ETx-22's design. The pipeline had a single platform asset rather than a diversified oncology portfolio.

As of mid-2026, Emergence has no active clinical programs. The termination of LY4101174's Phase I study in April 2026 ended the company's sole clinical-stage asset, and it now exists as a dormant legal subsidiary of Eli Lilly rather than an active development entity. The scientific and operational personnel absorbed from the 2023 acquisition are integrated into Lilly's broader ADC and oncology organization, though any ongoing contribution to Lilly's LY4052031 program has not been publicly characterized.

The Emergence acquisition's legacy now rests on whether Lilly's Nectin-4 strategy as a whole succeeds — and on what data eventually emerges from the terminated LY4101174 study. Key watchpoints include:

Data disclosure from the 143-patient LY4101174 Phase I cohort: even terminated studies generate safety and preliminary efficacy signals that could inform ADC field understanding.
LY4052031 Nexus-01 (NCT06465069) progression: this is now the program that will determine whether Lilly's $600 million Nectin-4 bet pays off, and Phase I readouts will be closely watched against enfortumab vedotin benchmarks.
Whether the tumor-specific deconjugation engineering from ETx-22 has been incorporated into Lilly's broader ADC design philosophy, even if the specific asset was shelved.
Competitive pressure from enfortumab vedotin plus pembrolizumab, which set a high combination-therapy bar in urothelial cancer that any next-generation Nectin-4 ADC will need to match or exceed.

Want to Update your Company's Profile?